Research: Endo Pharmaceuticals
Pharmaceuticals » Endo Pharmaceuticals
Click here to sign up for a Caris Research Account
1/19/2010
(ENDP) ENDP-Lowering PT to $25 to Account for Lidoderm Threat - Reiterate 2*/AA Based on Cash Flow & Earnings
No introduction text is currently available for this report.
10/29/2009
(ENDP) ENDP - 3Q Ends Up a Miss & Raise – Own ENDP for Earnings & Cash Flow & Trading at 8x 2009 EPS
No introduction text is currently available for this report.
10/27/2009
(ENDP) ENDP - 3Q Preview – A Likely to Beat & Raise for 2H09
No introduction text is currently available for this report.
9/01/2009
(ENDP) ENDP - We Would Own ENDO Nebido or Not. Reiterate 2/AA and $28 PT in front of Wednesday Nebido PDUFA
No introduction text is currently available for this report.
7/30/2009
(ENDP) ENDP Continues to Roll: 2Q09 Beats Top & Bottom,FY09 EPS Guidance Too Low – Raising Price Target to $28
No introduction text is currently available for this report.
4/30/2009
(ENDP) ENDP - 1Q09 Beats Top & Bottom Line. Lidoderm Weakness Should Reverse, ’09 Guidance Appears Safe
No introduction text is currently available for this report.
3/16/2009
(ENDP) ENDP - Upgrading to 2*/Above Average, Bad News Appears Priced In, +25% Upside to Price Target
No introduction text is currently available for this report.
2/26/2009
(ENDP) ENDP - 4Q EPS Expected to Be Strong, Indevus Acquisition the Focus of the Story – Maintain 3*/Average Rating
No introduction text is currently available for this report.
1/06/2009
(ENDP) ENDP - Ready, Fire, Aim: Indevus Acquisition Misses The Mark – Downgrading from 2*/Above Average to 3*/Average.
No introduction text is currently available for this report.
1/05/2009
(ENDP) ENDP - Deal or No Deal? Downgrading from 1*/Buy to 2*/Above Average -- Maintain $28 Price Target
No introduction text is currently available for this report.
Depending on the investment objectives and financial information specific to your situation, the investments discussed or recommended on this website may or may not be suitable for you. It is your responsibility to consider any investment decision carefully. The information contained on this website should not be construed as advice designed to meet the particular needs of any investor. Past performance is not necessarily indicative of future performance, and does not guarantee future results. The price and/or value of any security noted directly or indirectly on this website may fluctuate adversely to your interests, and/or those of other investors. Caris & Company accepts no liability whatsoever for loss or damage of any sort arising out of use of all or part of any information on this website.